北陆药业: 关于北陆转债赎回实施暨即将停止转股的重要提示性公告

Core Viewpoint - The company announces the mandatory redemption of its convertible bonds ("北陆转债") at a price of 101.64 CNY per bond, effective after the market closes on August 4, 2025, urging investors to convert their bonds before the deadline to avoid potential losses [1][2][9]. Summary by Sections Convertible Bond Basic Information - The total issuance of the convertible bonds was 500 million CNY, approved by the China Securities Regulatory Commission [2]. - The bonds were issued on December 11, 2020, with a conversion period from June 11, 2021, to December 6, 2026 [2]. Conversion Price Adjustments - The initial conversion price was set at 11.41 CNY per share, which was later adjusted downwards to 8.75 CNY due to market conditions and corporate actions [3][4][5]. - The current conversion price is 7.02 CNY per share, effective from May 19, 2025 [6]. Conditional Redemption Terms - The company has the right to redeem the bonds if the stock price exceeds 130% of the conversion price for 15 trading days within a 30-day period [7]. - The redemption was triggered as the stock price was above 9.13 CNY (130% of 7.02 CNY) for the required duration [7][8]. Redemption Implementation - The redemption price is calculated as 101.64 CNY per bond, which includes accrued interest [9]. - The redemption process will begin on July 31, 2025, when trading of the bonds will cease, and conversion will stop on August 5, 2025 [9][10]. Shareholder Actions and Notifications - Bondholders must process their conversion through their respective securities firms, and any unconverted bonds will be redeemed at the specified price [9][10]. - The company will publish announcements regarding the redemption results and the delisting of the bonds from the Shenzhen Stock Exchange [9][10].